Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Horizon Therapeutics plc

< Previous 1 2 3 4 5 6 Next >
New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Results from PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) in Kidney Transplant Recipients with Uncontrolled Gout Presented as Part of American Society of Nephrology (ASN) Kidney Week
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’s Commitment to Improving Outcomes for People Living with Uncontrolled Gout
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Participate in Upcoming Conferences
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021
From Horizon Therapeutics plc
Via Business Wire
Tickers HZNP
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.